Abstract
In recent decades we have seen a surge in the incidence of diabetes in industrialized nations; a threat which has now extended to the developing world. Type 2 diabetes is associated with significant microvascular and macrovascular disease, with considerable impact on morbidity and mortality. Recent evidence has cast uncertainty on the benefits of very tight glycaemic goals in these individuals. The natural history of disease follows an insidious course from disordered glucose metabolism in a pre-diabetic state, often with metabolic syndrome and obesity, before proceeding to diabetes mellitus. In the research setting, lifestyle, pharmacological and surgical intervention targeted against obesity and glycaemia has shown that metabolic disturbances can be halted and indeed regressed if introduced at an early stage of disease. In addition to traditional anti-diabetic medications such as the glinides, sulphonylureas and the glitazones, novel therapies manipulating the endocannabinoid system, neurotransmitters, intestinal absorption and gut hormones have shown dual benefit in weight loss and glycaemic control normalisation. Whilst these treatments will not and should not replace lifestyle change, they will act as invaluable adjuncts for weight loss and aid in normalising the metabolic profile of individuals at risk of diabetes. Utilizing novel therapies to prevent diabetes should be the focus of future research, with the aim of preventing the challenging microvascular and macrovascular complications, and ultimately cardiovascular death.
Keywords: Diabetes, obesity, cardiometabolic, cardiovascular disease, metabolic syndrome, weight loss, renin-angiotensinaldosterone system, preventive medicine, vascular disease.
Current Vascular Pharmacology
Title:Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Volume: 12 Issue: 1
Author(s): Kaivan Khavandi, Jack Brownrigg, Mohammed Hankir, Harpreet Sood, Naveed Younis, Joy Worth, Adam Greenstein, Handrean Soran, Anthony Wierzbicki and David J. Goldsmith
Affiliation:
Keywords: Diabetes, obesity, cardiometabolic, cardiovascular disease, metabolic syndrome, weight loss, renin-angiotensinaldosterone system, preventive medicine, vascular disease.
Abstract: In recent decades we have seen a surge in the incidence of diabetes in industrialized nations; a threat which has now extended to the developing world. Type 2 diabetes is associated with significant microvascular and macrovascular disease, with considerable impact on morbidity and mortality. Recent evidence has cast uncertainty on the benefits of very tight glycaemic goals in these individuals. The natural history of disease follows an insidious course from disordered glucose metabolism in a pre-diabetic state, often with metabolic syndrome and obesity, before proceeding to diabetes mellitus. In the research setting, lifestyle, pharmacological and surgical intervention targeted against obesity and glycaemia has shown that metabolic disturbances can be halted and indeed regressed if introduced at an early stage of disease. In addition to traditional anti-diabetic medications such as the glinides, sulphonylureas and the glitazones, novel therapies manipulating the endocannabinoid system, neurotransmitters, intestinal absorption and gut hormones have shown dual benefit in weight loss and glycaemic control normalisation. Whilst these treatments will not and should not replace lifestyle change, they will act as invaluable adjuncts for weight loss and aid in normalising the metabolic profile of individuals at risk of diabetes. Utilizing novel therapies to prevent diabetes should be the focus of future research, with the aim of preventing the challenging microvascular and macrovascular complications, and ultimately cardiovascular death.
Export Options
About this article
Cite this article as:
Khavandi Kaivan, Brownrigg Jack, Hankir Mohammed, Sood Harpreet, Younis Naveed, Worth Joy, Greenstein Adam, Soran Handrean, Wierzbicki Anthony and Goldsmith J. David, Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990118
DOI https://dx.doi.org/10.2174/15701611113119990118 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Targeting Cerebral Vascular Injury for Intervention
Current Drug Delivery Synthesis and Immunosuppressive Activity of New Mycophenolic Acid Derivatives
Medicinal Chemistry Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Novel Approaches to the Treatment of Obesity and Type 2 Diabetes Mellitus: Bioactive Leptin-Related Synthetic Peptide Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery An Insight into the Combat Strategies for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1)
Current Drug Metabolism Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women
Current Molecular Medicine The Boundary between Hypochondriasis, Personality Dysfunction, and Trauma
Current Psychiatry Reviews Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Insulin Releasing Properties of the Temporin Family of Antimicrobial Peptides
Protein & Peptide Letters Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Current Diabetes Reviews Vitamin D Replacement and Type 2 Diabetes Mellitus
Current Diabetes Reviews Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis
Recent Patents on Drug Delivery & Formulation